Mito-apocynin (C11) |
| Catalog No.GC61068 |
경구 활성 미토콘드리아 표적 트리페닐포스포늄(TPP) 기반 화합물인 미토-아포시닌(C11)은 아포시닌 부분을 TPP+ 양이온과 접합시켜 합성됩니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1254044-38-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Mito-apocynin (C11), an orally active mitochondria-targeted triphenylphosphonium (TPP)-based compound, is synthesized by conjugating the Apocynin moiety with a TPP+ cation. Mito-apocynin (C11) selectively targets mitochondria, and shows neuroprotective effect. Mito-apocynin (C11) prevents hyposmia and corrects deficits in motor function[1].
Mito-apocynin-C11 (3 mg/kg; oral gavage; 3x/wk from 3 months of age until 15 months) markedly improves the coordinated motor function and olfactory function in LRRK2R1441G mice[1]. Animal Model: LRRK2R1441G mice[1]
[1]. Dranka BP, et al. A novel mitochondrially-targeted apocynin derivative prevents hyposmia and loss of motor function in the leucine-rich repeat kinase 2 (LRRK2(R1441G)) transgenic mouse model of Parkinson's disease. Neurosci Lett. 2014 Nov 7;583:159-64.
Average Rating: 5 (Based on Reviews and 14 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *